Epigenetic Reprogramming (Yamanaka Factors / OSK)

Epigenetic reprogramming is the most advanced intervention for reversing biological age, shifting from Nobel Prize-winning theory to clinical trials, and it is faster and more comprehensive than the age-related degeneration that senolytics or NAD+ boosters can only delay. David Sinclair's 2020 Harvard study showed that OSK transcription factor expression reversed epigenetic age in mouse retinal cells, achieving a 30% improvement in nerve regeneration. This partial reprogramming resets DNA methylation patterns without inducing pluripotency, addressing epigenetic drift—a core aging hallmark identified by the Horvath clock. The 2025 PMC12610414 study confirmed that OSKM resets gene expression to youthful profiles across multiple tissues. OSK reprogramming costs 30% less per year than senolytic therapy in projected clinical pricing.